Physician profile
Andrew C Bolin
NPI 1093841413
$10,295.49
in general payments reported to CMS, 2019-2025
50 companies · $2,143 in 2025
The $2,143 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053 · 2020: $711 · 2021: $1,226 · 2022: $1,049 · 2023: $1,732 · 2024: $2,382 · 2025: $2,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,230 · Education: $27.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,229.58 |
| Education | $27.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,717.31 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $986.18 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $906.27 | 2019-2025 | |
| Janssen Biotech, INC. | $880.95 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $795.27 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $372.39 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $288.65 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $266.62 | 2022-2025 | Dupixent |
| Evoke Pharma, INC. | $238.96 | 2021-2025 | Gimoti |
| Genzyme Corporation | $204.67 | 2024-2025 | |
| Daiichi Sankyo INC. | $201.01 | 2019-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $193.51 | 2019-2024 | Zerbaxa, Dificid |
| Ardelyx, INC. | $175.28 | 2023-2025 | Ibsrela |
| Ucb, INC. | $168.09 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $165.17 | 2019-2025 | Ocaliva |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,805.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.